HALOZYME THERAPEUTICS, INC. (HALO) Net margin 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) net profit margin by fiscal year — reported net income divided by reported revenue.
22.7%FY2025 · since FY2016: -70.2% → 22.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 22.7% | -21.0 pp |
| FY2024 | 43.7% | +9.8 pp |
| FY2023 | 34.0% | +3.3 pp |
| FY2022 | 30.6% | -60.2 pp |
| FY2021 | 90.8% | +42.6 pp |
| FY2020 | 48.2% | +85.1 pp |
| FY2019 | -36.9% | +16.0 pp |
| FY2018 | -52.9% | -72.8 pp |
| FY2017 | 19.9% | +90.1 pp |
| FY2016 | -70.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating marginHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →